Clinical trial
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting…
NCT02938520 · ViiV Healthcare, Industry · Active, not recruiting
Key facts
| NCT number | NCT02938520 |
|---|---|
| Title | Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants |
| Official title | A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1… |
| Lead sponsor | ViiV Healthcare, Industry |
| Collaborators | Janssen Pharmaceuticals Industry GlaxoSmithKline |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet |
| Enrollment | 631 |
| Start date | Oct 27, 2016 |
| Primary completion | Aug 30, 2018 |
| Completion | Dec 31, 2025 |
| First posted | Oct 19, 2016 |
| Last update posted | Dec 31, 2025 |
| Countries | Canada, France, Germany, Italy, Japan, Netherlands, Russia, South Africa, Spain, United Kingdom, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: